Semaglutide as an important medicine for managing combined heart, kidney, and metabolism problems

R MacIsaac has received research grants from Novo Nordisk, Servier, Medtronic, The Rebecca Cooper Medical Research Foundation, St Vincent’s Research Foundation, The Juvenile Diabetes Research Foundation, Grey Innovations, The Diabetes Australia Research Trust/Program and The National Health and Medical Research Council of Australia. He has also received honoraria for lectures from Eli Lilly, Novo Nordisk, Sanofi Aventis, Astra Zeneca, Merck Sharp & Dohme, Novartis and Boehringer Ingelheim. He is on the advisory boards for Novo Nordisk, Boehringer Ingelheim-Eli Lilly Diabetes Alliance, Astra Zeneca, and Merck Shape and Dohme. Novo Nordisk, Sanofi, Boehringer Ingelheim and Astra Zeneca have supplied travel support. He has been a principal investigator for industry-sponsored clinical trials by Novo Nordisk, Sanofi, Bayer, Johnson-Cilag and AbbVie. He was an investigator for the semaglutide trials SUSTAIN-6 and FLOW and was on the global expert panel for the FLOW trial. The author has no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. Brad Dalton of medScript Communications provided medical writing and editorial support for this article, which Novo Nordisk funded.